Business
Arecor and TRx Biosciences research collaboration
Arecor and TRx Biosciences research collaboration.
About this update from Arecor Therapeutics Plc
[{"type":"text","content":"\n\nArecor Therapeutics plc\n(\"Arecor\" or the \"Company\")\n \nARECOR AND TRx BIOSCIENCES ESTABLISH RESEARCH COLLABORATION TO DEVELOP ORAL GLP-1 WITH ENHANCED BIOAVAILABILITY\n \n- Companies to combine proprietary technologies to formulate an oral semaglutide (GLP-1 receptor agonist) product with enhanced bioavailability\n- Collaboration focused on overcoming the challenges of oral peptide delivery using a novel lipid technology to provide a more convenient treatment option for patients with diabetes and obesity\n- Potential to expand collaboration across multiple oral peptide products and combination therapies in growing global market\n \nCambridge, UK, 12 March 2024: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today's therapies to enable healthier lives, and TRx Biosciences Limited, a drug development company applying novel lipid technology to the oral delivery of challenging molecules, today announced a research collaboration for the formulation development of an oral glucagon-like peptide-1 (GLP-1) receptor agonist product.\n \nGLP-1 receptor agonists are a class of therapeutic peptides used to treat type 2 diabetes and obesity, in a global market predicted to reach $80-$100+ billion by 20301. Oral delivery of this class of drug is extremely challenging owing to the proteolytic nature of the digestive system which significantly reduces bioavailability. Injection remains the most common delivery form for therapeutic peptide drugs, limiting adoption, compliance and usage among patients, who would prefer a simpler, more practical oral therapy.\n \nThe only GLP-1 receptor agonist currently available to patients in pill form - Novo Nordisk's semaglutide (Rybelsus®) - has oral bioavailability of less than 1%2. Using TRx Biosciences' LipiCore™ oral delivery technology alongside Arecor's formulation platform, Arestat™, the companies intend to jointly develop an oral GLP-1 receptor agonist product with enhanced physicochemical properties that can achieve higher oral bioavailability and stability.\n \nSarah Howell, Chief Executive Officer of Arecor, said: \"As the global market for GLP-1 receptor agonists grows and their use increases, significant challenges remain in their oral deliv...